Answers are grounded in this paper and cite their sources.
Hodgkin’s lymphoma (HL) is a B-cell malignancy with a classical bimodal distribution with incidence peaking in the third and sixth decades of life. The purpose of this review is to describe the current unmet medical need for relapsing/refractory HL and the main data of emerging treatments, including brentuximab vedotin, the immune checkpoint inhibitors nivolumab and pembrolizumab, as well as other compounds in development. Available guidelines for relapsing/refractory HL are discussed.
No takes yet. Share an insight, caveat, or question.
Perini et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: